目的探讨可溶性程序性死亡蛋白1(soluble programmed death protein 1,sPD-1)、可溶性程序性死亡蛋白配体1(soluble programmed death protein ligand 1,sPD-L1)在原发性肾病综合征(primary nephrotic syndrome,PNS)患者中的表达及其临...目的探讨可溶性程序性死亡蛋白1(soluble programmed death protein 1,sPD-1)、可溶性程序性死亡蛋白配体1(soluble programmed death protein ligand 1,sPD-L1)在原发性肾病综合征(primary nephrotic syndrome,PNS)患者中的表达及其临床意义。方法选择2016年4月至2019年4月我院收治的PNS患者87例作为病例组,同期在我院健康体检者87例作为对照组,比较两组血清sPD-1、sPD-L1水平,比较不同病理类型PNS患者血清sPD-1、sPD-L1水平,比较不同转归情况PNS患者血清sPD-1、sPD-L1水平,采用P earson相关分析PNS患者血清sPD-1、sPD-L1水平的相关性,采用多因素Logistic回归分析PNS发生的危险因素。结果病例组治疗前血清sPD-1、sPD-L1水平明显高于对照组,差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗前血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗后血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗前、后血清sPD-1、sPD-L1水平差异均具有统计学意义(P<0.05);不同转归情况PNS患者治疗后血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);PNS患者血清sPD-1、sPD-L1水平呈正相关(P<0.05);sPD-1、sPD-L1是PNS的影响因素(P<0.05)。结论sPD-1、sPD-L1在原发性肾病综合征患者血清中呈高表达,sPD-1、sPD-L1检测对肾病综合征预后评估有潜在价值。展开更多
Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From J...Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From January 2016 to October 2017, 36 cases with acute myeloid leukemia were selected as AML group. After 1-2 courses of standard chemotherapy, 27 cases with complete remission were selected as complete remission group, 9 cases without improvement as a group. In the same period, 20 healthy patients were selected as the healthy control group. The expression levels of sPD-L1 and VEGF were detected by enzyme-linked immunoassay (ELISA).Results: The expression of sPD-L1 and VEGF in serum of the initial and unrelieved AML patients was significantly higher than that in the healthy control group, and the difference was statistically significant. After 1-2 courses of standard chemotherapy, the expression of sPD-L1 and VEGF in the serum of patients with complete remission was significantly lower than that in the initial treatment group, and the difference was statistically significant. There was no statistically significant difference between the total relief group and the control group. There is a significant positive correlation between the two expressions. Conclusions: The high expression of sPD-L1and VEGF in serum may be related to the occurrence, development and prognosis of AML. Therefore, the joint detection of sPD-L1 and VEGF is of some significance to the early diagnosis, monitoring efficacy and prognosis of AML patients.展开更多
文摘目的探讨可溶性程序性死亡蛋白1(soluble programmed death protein 1,sPD-1)、可溶性程序性死亡蛋白配体1(soluble programmed death protein ligand 1,sPD-L1)在原发性肾病综合征(primary nephrotic syndrome,PNS)患者中的表达及其临床意义。方法选择2016年4月至2019年4月我院收治的PNS患者87例作为病例组,同期在我院健康体检者87例作为对照组,比较两组血清sPD-1、sPD-L1水平,比较不同病理类型PNS患者血清sPD-1、sPD-L1水平,比较不同转归情况PNS患者血清sPD-1、sPD-L1水平,采用P earson相关分析PNS患者血清sPD-1、sPD-L1水平的相关性,采用多因素Logistic回归分析PNS发生的危险因素。结果病例组治疗前血清sPD-1、sPD-L1水平明显高于对照组,差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗前血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗后血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);3种病理类型的PNS患者治疗前、后血清sPD-1、sPD-L1水平差异均具有统计学意义(P<0.05);不同转归情况PNS患者治疗后血清sPD-1、sPD-L1水平差异具有统计学意义(P<0.05);PNS患者血清sPD-1、sPD-L1水平呈正相关(P<0.05);sPD-1、sPD-L1是PNS的影响因素(P<0.05)。结论sPD-1、sPD-L1在原发性肾病综合征患者血清中呈高表达,sPD-1、sPD-L1检测对肾病综合征预后评估有潜在价值。
文摘Objective: To investigate the expression level and correlation of soluble programmed death factor (sPD-L1) and vascular endothelial growth factor (VEGF) in serum of patients with acute myeloid leukemia.Methods: From January 2016 to October 2017, 36 cases with acute myeloid leukemia were selected as AML group. After 1-2 courses of standard chemotherapy, 27 cases with complete remission were selected as complete remission group, 9 cases without improvement as a group. In the same period, 20 healthy patients were selected as the healthy control group. The expression levels of sPD-L1 and VEGF were detected by enzyme-linked immunoassay (ELISA).Results: The expression of sPD-L1 and VEGF in serum of the initial and unrelieved AML patients was significantly higher than that in the healthy control group, and the difference was statistically significant. After 1-2 courses of standard chemotherapy, the expression of sPD-L1 and VEGF in the serum of patients with complete remission was significantly lower than that in the initial treatment group, and the difference was statistically significant. There was no statistically significant difference between the total relief group and the control group. There is a significant positive correlation between the two expressions. Conclusions: The high expression of sPD-L1and VEGF in serum may be related to the occurrence, development and prognosis of AML. Therefore, the joint detection of sPD-L1 and VEGF is of some significance to the early diagnosis, monitoring efficacy and prognosis of AML patients.